Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Study assessing persistence and effectiveness of PCSK9i in clinical practice setting in FH patients from the SAFEHEART register with long-term follow-up.

Next Previous
Trial Profile

Study assessing persistence and effectiveness of PCSK9i in clinical practice setting in FH patients from the SAFEHEART register with long-term follow-up.

Status: Recruiting
Phase of Trial: Phase IV

Latest Information Update: 12 Oct 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Alirocumab (Primary) ; Evolocumab (Primary)
  • Indications Hypercholesterolaemia
  • Focus Therapeutic Use
  • Acronyms SAFEHEART

Most Recent Events

  • 12 Oct 2022 New trial record
  • 29 Aug 2022 Results presented at the ESC Congress 2022 - Annual Congress of the European Society of Cardiology

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top